Publication date: Apr 02, 2019
SAN CARLOS, Calif. , April 1, 2019 /PRNewswire/ — Apexigen, Inc. , a clinical-stage biopharmaceutical company, today presented new clinical data on APX005M at the American Association for Cancer Research (AACR) Annual Meeting, taking place March 29 – April 3, 2019 in Atlanta, GA.
“We are excited to have new clinical data presented at AACR on our CD40 antibody APX005M in combination therapy, highlighting the breadth of our clinical development program targeting difficult-to-treat types of cancer,” said Ovid Trifan, M. D., Ph. D., Chief Medical Officer and Senior Vice President of Clinical Development of Apexigen.
“Yesterday, clinical data in metastatic pancreatic cancer were presented in a plenary session, showing APX005M in combination therapy was well-tolerated and induced promising tumor shrinkage in 20 of 24 evaluable patients.
Today, we are presenting clinical data from our ongoing Phase 1b/2 clinical trial in patients with metastatic melanoma demonstrating that APX005M is well tolerated in combination with nivolumab and triggers responses in patients who have progressed on anti-PD-1 therapy.
The Phase 2 dose-expansion portion of this clinical trial followed a Simon 2-stage design and included two parallel cohorts of patients treated with the RP2D of APX005M with nivolumab.
For additional information on this trial (NCT03123783), please visit Data Presentation at AACR 2019 Annual Meeting Late-breaking Abstract Title: Phase Ib/II clinical trial of CD40 agonistic antibody APX005M in combination with nivolumab (nivo) in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC) (Abstract #CT089) Poster Session Date and Time: Monday, April 1, 2019 1:00 PM – 5:00 PM ET Poster Session: Phase 1 Clinical Trials Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 16 About APX005M APX005M is a humanized monoclonal antibody designed to stimulate the anti-tumor immune response.
APX005M is currently in Phase 2 clinical development for the treatment of cancers such as pancreatic cancer, melanoma, esophageal and gastroesophageal junction cancers, non-small cell lung cancer, renal cell carcinoma, sarcomas, and pediatric brain cancer in various combinations with immunotherapy, a cancer vaccine, chemotherapy or radiation therapy.
|pathway||BSID||Renal cell carcinoma|
|disease||DOID||renal cell carcinoma|
|disease||MESH||renal cell carcinoma|
|pathway||BSID||Non-small cell lung cancer|
|disease||MESH||non-small cell lung cancer|
|disease||DOID||non-small cell lung cancer|